▶ Freely access a vast video library on NASH and NAFLD, its management and diagnosis along with the latest on pan-PPAR agonist, lanifibranor.
Nash Videos
NAFLD: time to update the terminology? By Prof. S. Francque
2020 started with an important discussion about the terminology to be used regarding Non Alcoholic Fatty Liver Disease (NAFLD). In this exclusive interview for the PanNASH web site, Prof Sven Francque discusses the rationale of this change and the possible impact in clinical practice
View More ⏩NAFLD: time to update the terminology? By Prof. S. FrancqueNASH and NAFL: it is not only about liver but it is a complex inter-organ crosstalk in which adipose tissue dysfunction is an important driver of the disease.
In this Expert perspective video, Prof Sven Francque explains how to make the distinction between NAFL and NASH. This is important even though in clinical practice there is a continuum between the two. In the pathophysiology of NASH there is a complex interplay between different organs. Adipose tissue dysfunction is an important driver of disease.
View More ⏩NASH and NAFL: it is not only about liver but it is a complex inter-organ crosstalk in which adipose tissue dysfunction is an important driver of the disease.NAFLD: a hegemonic disease by Prof. S. Francque
In this Expert perspective video, Prof Sven Francque explains how to make the distinction between NAFL and NASH. This is important even though in clinical practice there is a continuum between the two. In the pathophysiology of NASH there is a complex interplay between different organs. Adipose tissue dysfunction is an important driver of disease.
View More ⏩NAFLD: a hegemonic disease by Prof. S. Francque
PPARs: State-of-the-art by Prof. J.-F. Dufour
Prof. Jean-François Dufour (Switzerland) explores PPARs to NAFLD28 as a systemic disease with metabolic changes in Adipose tissue, skeletal muscle, liver and endothelium.
View More ⏩PPARs: State-of-the-art by Prof. J.-F. DufourThe role of a global holistic approach in NASH management: important messages
Prof. Rautou, France, discusses a critical component of the diagnosis and management of NASH: biomarkers. There are 2 aspects: fibrosis and diagnosis. Diagnosis is a field of investigations. Microvesicles could play a role.
View More ⏩The role of a global holistic approach in NASH management: important messages
The role of insulin resistance and insulin-sensitizers in NASH management: tips for the practicing clinician
Prof Kenneth Cusi, USA, discusses the role of insulin sensitizers in NASH, and particularly how lifestyle interventions including weight loss can, in this context, be beneficial together with a pharmacological approach.
View More ⏩The role of insulin resistance and insulin-sensitizers in NASH management: tips for the practicing clinician
The role of comorbidities in NASH management: a holistic approach
Prof Jean-François Dufour, Switzerland, addresses the important problem of comorbidities in NASH management including diabetes, cardiovascular disease, cancer. This video was filmed in Boston during the Liver meeting 2019.
View More ⏩The role of comorbidities in NASH management: a holistic approach
The Role of Liver Sinusoidal Endothelial Cells
Prof. Rautou, France, discusses a critical component of the diagnosis and management of NASH: biomarkers. There are 2 aspects: fibrosis and diagnosis. Diagnosis is a field of investigations. Microvesicles could play a role.
View More ⏩The Role of Liver Sinusoidal Endothelial Cells
What can we expect from PPAR agonists in the treatment of NASH?
Prof Manal Abdelmalek, USA highlights the role that PPAR agonists could play in the treatment of NASH. This video was filmed in Boston during the Liver meeting 2019.
View More ⏩What can we expect from PPAR agonists in the treatment of NASH?
Pre-clinical study with Lanifibranor – Prof Gracia-Sancho
Prof Gracia-Sancho, Spain, discusses his oral presentation at the Liver meeting 2019 in Boston and the reasons why PPAR agonists could be a very valuable therapeutic option for the treatment of advanced chronic liver disease.
View More ⏩Pre-clinical study with Lanifibranor – Prof Gracia-Sancho
Why are NASH patients at increased CV risk & how can PPAR agonists potentially improve outcomes?
Prof Michael Roden, Germany discusses the reasons why patients with NASH have an increased cardiovascular risk and the potential for PPAR agonists to improve outcomes. This video was filmed in Boston during the Liver meeting 2019.
View More ⏩Why are NASH patients at increased CV risk & how can PPAR agonists potentially improve outcomes?
The role of PPARs in NASH fibrogenesis
Prof Gyongyi Szabo, USA discusses the role of PPARs in NASH fibrogenesis. This video was filmed in Boston during the Liver meeting 2019.
View More ⏩The role of PPARs in NASH fibrogenesis
SUBSCRIBE & FOLLOW US
SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES